|
|
 |
|
|
Press Releases and Announcements
- (Canton, Mass. / Washington D.C.) –
April 17, 2008
Organogenesis, Inc. to Develop Regenerative Medicine Therapies for U.S. Military Battlefield Injuries
Consortium wins grant to form new Armed Forces Institute of Regenerative Medicine (AFIRM).
(Read full version of this press release...)
- (Canton, Mass) – April 3rd, 2008
Governor Patrick Announces Life Sciences Initiative Victory With Organogenesis' New Headquarters
Regenerative Medicine leader to expand space and employees in Massachusetts, encompassing over 250,000 square feet for new global headquarters.
- (Canton, Mass) – March 17, 2008
Organogenesis Names Regenerative Medicine Expert Dr. Damien Bates Vice President, Medical Affairs
Organogenesis, Inc., announced today that Damien Bates, MD, PhD, FRACS (Plast.), has joined the company as vice president of medical affairs.
(Read full version of this press release...)
- (Canton, Mass) – February 11, 2008
Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers
Organogenesis, Inc., the first company to successfully mass-produce living regenerative medicine products, is again breaking new ground by launching the first-ever direct-to-consumer (DTC)—educational campaign for a living cell-based therapy.
(Read full version of this press release...)
- (Canton, Massachusetts / Baton Rouge, Louisiana) – January 25, 2008
Organogenesis, Inc. Announces Acquisition of NanoMatrix, Inc.
Organogenesis, Inc., the world's most successful regenerative medicine company, announced today the strategic acquisition of Baton Rouge-based NanoMatrix, Inc.
(Read full version of this press release...)
- (Canton, Mass/Shanghai) – December 10, 2007
Organogenesis, Inc. Signs Memorandum of Understanding with Chinese Regenerative Medicine Company
Organogenesis, Inc., the world's most successful regenerative medicine company, announced today that it has signed a memorandum of understanding with China’s National Tissue Engineering Center (NTEC), a leading stem cell and regenerative medicine consortium, headquartered in Shanghai.
(Read full version of this press release...)
- (London, England/Canton, Massachusetts) – November 16, 2007
Stephen Farrell of Organogenesis Addresses Life Sciences Leaders at 5th Annual Commercial Translation for Regenerative Medicine in London
Organogenesis, Inc., the world's most successful regenerative medicine company, has announced that Stephen Farrell, Vice President of Marketing will address the 5th Annual Commercial Translation for Regenerative Medicine conference, taking place this week in London.
(Read full version of this press release...)
- (Leipzig, Germany / Canton, Massachusetts) – October 18, 2007
CEO of World’s Leading Regenerative Medicine Company, Organogenesis, Gives Keynote Address at World Congress of Regenerative Medicine in Germany
The prestigious 3rd Annual World Congress of Regenerative Medicine is kicking off today in Leipzig, Germany with an opening keynote address from Geoff MacKay, CEO of Organogenesis, Inc.
(Read full version of this press release...)
- (Canton, MA) – July 9, 2007
Bioresorbable Collagen Scaffold Placed Inside the Heart Revolutionizes Treatment
BioSTAR® (NMT Medical, Boston, MA), a device that incorporates a bioresorbable collagen scaffold used to treat patent foramen ovale (PFO) has received regulatory approval in Canada and Europe.
(Read full version of this press release...)
- (Canton, MA) – May 31, 2007
On Heels of Life Sciences Initiative, Governor Patrick Announces Organogenesis to Expand in Massachusetts
World's first profitable regenerative medicine company to grow in Massachusetts due to state's newly unveiled life science initiative.
(Read full version of this press release...)
- (Canton, MA) – May 7, 2007
CEO of World's First Profitable Regenerative Medicine Company, Organogenesis, Details Path To Profitability For The Regenerative Medicine Field
Geoff MacKay, CEO of ORGANOGENESIS, Inc., will present at the world's leading biotech conference, BIO 2007 on May 8, 2007 in Boston, MA.
(Read full version of this press release...)
- (Canton, MA) – January 2006
Organogenesis Inc. Announces Further Sales Force Expansion
Due to the rapid
uptake of Apligraf® , the world's leading tissue
regeneration product, Organogenesis announces the third sales force
expansion in the last two years. The unique skills required to integrate
a cell-based tissue regeneration product into the health care system
requires sales specialists capable of providing a breadth and depth
of the most relevant scientific learnings to top wound specialists
around the country.
- (Canton, MA) – April 2005
Same Apligraf® Cell Viability & Structure….Now
with a 10 Day Shelf Life!
Organogenesis Inc.
announces that its lead product Apligraf® now has
an extended shelf life of 10 days in the hands of wound healing
specialists. Apligraf® is the only tissue regeneration
product approved by FDA to treat both venous leg ulcers and diabetic
foot ulcers. The significantly longer shelf life of this living,
cell-based product provides greater convenience to the wound healing
centers around the country who routinely order Apligraf® to close wounds faster than conventional approaches.
- (Canton, MA) – February 2005
Apligraf® Treats Over 100,000 Patients in the USA
Apligraf® , the world's leading tissue regeneration product, has been
applied to over 100,000 patients. This constitutes over two-thirds
of all living, cell-based product applications across all therapeutic
areas. The initial FDA approvals for Apligraf® ushered
in the new era of tissue regeneration. This "100,000 patient
check-up" highlights the growing success the product has achieved
as a key technology in closing chronic wounds.
- (Canton, MA) – January 2005
Organogenesis Inc. Launched Major Study to Treat Pressure Ulcers
Pressure ulcers
(also known as "bedsores") arise as a result of skin
breakdown, usually over bony prominences, occurring as a result
of prolonged pressure. Patients with limited mobility, such as those
bedridden, are particularly prone to pressure ulcers. Pressure ulcers
can occur most anywhere in the body but are especially troublesome
in the pelvic area. The severity of pressure ulcers can range from
relatively minor skin redness (Stage I) to major wounds that extend
all the way to bone (Stage IV). Organogenesis is studying the use
of Apligraf® compared to conventional treatment for
treatment of Stage III pressure ulcers located in the pelvic area.
Fifteen medical centers are participating in this groundbreaking
Phase III study.
|
|
| |
|
|
